This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study alirocumab (REGN727/ SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT).

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Age less than 18 years or legal age of adulthood, whichever is greater

LDL-C less than 70 mg/dL (1.81 mmol/L) and with cardiovascular disease

LDL-C less than 100 mg/dL (2.59 mmol/L) and without cardiovascular disease

Fasting serum triglycerides greater than 400 mg/dL (4.52 mmol/L)

Known history of homozygous familial hypercholesterolemia

(The inclusion/exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01709500